13F filing recap · Q4 2024
What did Causeway Capital Management buy in Q4 2024?
Reported stock-position changes between this filing and the previous one. US-listed stocks across every Causeway account, including accounts that belong to no fund below.
Stock value
$4.39B
Positions
107
Estimated turnover
44.2%
Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.
Quarter in review
Causeway Capital Management opened new positions in Barrick Mining, Merck, Biogen, XP, Sea Limited, Ally Financial, Smith & Nephew, Anglogold Ashanti, Atour Lifestyle, and several smaller names. It exited Bristol-Myers Squibb, Fiserv, Petrobras, Seagate Technology, National Grid, and others. The firm substantially increased Canadian Pacific Kansas City and Axis Capital, while sharply boosting Boeing, Credicorp, and ZIM Integrated Shipping. It substantially trimmed Smurfit Westrock, Genpact, PDD Holdings, Live Nation, and Takeda Pharmaceutical.